R

Redhill Biopharma Ltd
D

RDHL

1.84000
USD
-0.01
(-0.54%)
Market Closed
Volume
219
EPS
-1
Div Yield
-
P/E
-0
Market Cap
3,255,181
Related Instruments
A
AKRO
-2.565
(-5.24%)
46.380 USD
A
ALLO
-0.05500
(-5.02%)
1.04000 USD
D
DRRX
-0.03100
(-5.47%)
0.53590 USD
G
GNFT
0.09000
(2.13%)
4.32000 USD
I
IMUX
-0.00820
(-0.89%)
0.91510 USD
K
KALA
-0.10000
(-2.53%)
3.86000 USD
R
RCKT
-0.28500
(-4.35%)
6.26500 USD
S
SNGX
-0.02000
(-1.09%)
1.81000 USD
More
News

Title: Redhill Biopharma Ltd

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-relatedproducts in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.